2002071199

18 NOV 2002

162162

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 December 2001 (20.12.2001)

PCT

(10) International Publication Number
WO 01/96338 A1

(51) International Patent Classification[7]: C07D 471/14, A61K 31/55 // (C07D 471/14, 243:00, 221:00, 221:00)

(21) International Application Number: PCT/CA01/00890

(22) International Filing Date: 14 June 2001 (14.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/212,329 16 June 2000 (16.06.2000) US
60/256,638 18 December 2000 (18.12.2000) US

(71) Applicant *(for all designated States except US)*: **BOEHRINGER INGELHEIM (CANADA) LTD.** [CA/CA]; 2100 Cunard Street, Laval, Québec H7S 2G5 (CA).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **SIMONEAU, Bruno** [CA/CA]; 2615, de la Volière, Laval, Québec H7L 3V6 (CA).

(74) Agent: **BERNIER, Louise, G.**; Boehringer Ingelheim (Canada) Ltd., 2100 Cunard, Laval, Québec H7S 2G5 (CA).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published:
— *with international search report*

[Continued on next page]


(54) Title: NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS




(I)




(II)



(III)



(IV)



(V)

(57) Abstract: Provided are compounds of general formula (I), wherein R^2 is selected from the group consisting of H, F, Cl, (C_{1-4}) alkyl, (C_{3-4}) cycloalkyl and CF_3; R^4 is H or Me; R^5 is H, Me or Et, with the proviso that R^4 and R^5 are not both Me, and if R^4 is Me then R^5 cannot be Et; R^{11} is Et, cyclopropyl, propyl, isopropyl, or isobutyl; and Q is selected from the group consisting of (II), (III), (IV) and (V); and pharmaceutically acceptable salts thereof, as inhibitors of HIV reverse transcriptase, wild-type and several mutant strains.

WO 01/96338 A1

ACTION

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.